ClearPoint Neuro stock slips as revenue misses estimates

ClearPoint Neuro Inc. (US18507C1099) stock is under pressure after the latest earnings update showed second-quarter 2026 revenue of $10.88 million and an EPS loss of $0.38, according to MarketBeat. The same source said the company missed the consensus estimate of $12.73 million in revenue and $0.29 per share.

Revenue and loss matter

The stock snapshot on September 4, 2026 showed CLPT at $13.78 to $14.09, with volume of 384,692 shares and a market capitalization of $425.78 million, while the 52-week range stretched from $8.27 to $30.10. That places the shares well below the upper end of the range, but still above the 52-week low.

For investors, the key point is the gap between the $10.88 million reported for the quarter and the $12.73 million estimate. The earnings miss was $0.09 per share, a concrete comparison that keeps the focus on execution rather than broad market sentiment.

Consensus stays cautious

MarketBeat also listed an average price target of $25.67 and a consensus rating of Hold based on 3 analysts. The implied upside from the snapshot is 83.9 percent versus the quoted price level.

A negative trailing twelve-month net margin of 81.76 percent and a return on equity of 188.09 percent underline how far ClearPoint Neuro still sits from clean profitability. The latest numbers show why cash generation and operating leverage remain the central issue.

ClearPoint Neuro platform

ClearPoint Neuro develops an MRI-guided therapy platform for minimally invasive neurosurgical procedures, a niche that ties product adoption directly to procedure volume and hospital execution. That makes the reported revenue figure more important than a simple product description.

Price and range

As of September 4, 2026, ClearPoint Neuro stock was quoted at $13.78 to $14.09 on MarketBeat, with the 52-week range at $8.27 to $30.10.